| dc.description.abstract | The national pharmaceutical market in Bangladesh has been increasing in recent years and currently the market stands at 142 billion BDT. Demand for good quality drugs is on the rise and the local market is expected to reach BD 160 billion by 2018. Bangladesh pharmaceutical companies supply generic products and can charge premiums for their products. The top 10 companies have about 67% of the market. It is very complicated to enter this sector due to a high investment.
GlaxoSmithKline Bangladesh Ltd is listed on the Dhaka Stock Exchange and has been fairly successful in the stock market. GlaxoSmithKline Bangladesh Limited has a very high dividend payment rate that primarily attracts the company's shareholders. The profitability of this company declined in 2016. The company has a very low current ratio that could pose a threat to it. Therefore, the company should focus more on this problem and should be careful to monitor the debts. Although, after comparing the financial report of GSK with that of Beximco Pharmaceutical and Reckitt Benckiser, it was found that GSK had a good financial performance
It should work on expanding their product line, as it has a narrow product line and should also improve their current relationship. Shareholders would benefit greatly if the company could increase its earnings per share ratio. To improve performance, GSK should focus more on expanding the product line and payment rate. | en_US |
